Bioengineered human heparin with anticoagulant activity. 2016

Megan S Lord, and Bill Cheng, and Fengying Tang, and J Guy Lyons, and Jelena Rnjak-Kovacina, and John M Whitelock
Graduate School of Biomedical Engineering, University of New South Wales, Sydney, NSW 2052, Australia. Electronic address: m.lord@unsw.edu.au.

Heparin is a carbohydrate anticoagulant used clinically to prevent thrombosis, however impurities can limit its efficacy. Here we report the biosynthesis of heparin-like heparan sulfate via the recombinant expression of human serglycin in human cells. The expressed serglycin was also decorated with chondroitin/dermatan sulfate chains and the relative abundance of these glycosaminoglycan chains changed under different concentrations of glucose in the culture medium. The recombinantly expressed serglycin produced with 25mM glucose present in the culture medium was found to possess anticoagulant activity one-seventh of that of porcine unfractionated heparin, demonstrating that bioengineered human heparin-like heparan sulfate may be a safe next-generation pharmaceutical heparin.

UI MeSH Term Description Entries
D011509 Proteoglycans Glycoproteins which have a very high polysaccharide content. Proteoglycan,Proteoglycan Type H
D001777 Blood Coagulation The process of the interaction of BLOOD COAGULATION FACTORS that results in an insoluble FIBRIN clot. Blood Clotting,Coagulation, Blood,Blood Clottings,Clotting, Blood
D005818 Genetic Engineering Directed modification of the gene complement of a living organism by such techniques as altering the DNA, substituting genetic material by means of a virus, transplanting whole nuclei, transplanting cell hybrids, etc. Genetic Intervention,Engineering, Genetic,Intervention, Genetic,Genetic Interventions,Interventions, Genetic
D006493 Heparin A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts. Heparinic Acid,alpha-Heparin,Heparin Sodium,Liquaemin,Sodium Heparin,Unfractionated Heparin,Heparin, Sodium,Heparin, Unfractionated,alpha Heparin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000925 Anticoagulants Agents that prevent BLOOD CLOTTING. Anticoagulant Agent,Anticoagulant Drug,Anticoagulant,Anticoagulant Agents,Anticoagulant Drugs,Anticoagulation Agents,Indirect Thrombin Inhibitors,Agent, Anticoagulant,Agents, Anticoagulant,Agents, Anticoagulation,Drug, Anticoagulant,Drugs, Anticoagulant,Inhibitors, Indirect Thrombin,Thrombin Inhibitors, Indirect
D057809 HEK293 Cells A cell line generated from human embryonic kidney cells that were transformed with human adenovirus type 5. 293T Cells,HEK 293 Cell Line,HEK 293 Cells,Human Embryonic Kidney Cell Line 293,Human Kidney Cell Line 293,293 Cell, HEK,293 Cells, HEK,293T Cell,Cell, 293T,Cell, HEK 293,Cell, HEK293,Cells, 293T,Cells, HEK 293,Cells, HEK293,HEK 293 Cell,HEK293 Cell
D060847 Metabolic Engineering Methods and techniques used to genetically modify cells' biosynthetic product output and develop conditions for growing the cells as BIOREACTORS. Engineering, Metabolic
D033921 Vesicular Transport Proteins A broad category of proteins involved in the formation, transport and dissolution of TRANSPORT VESICLES. They play a role in the intracellular transport of molecules contained within membrane vesicles. Vesicular transport proteins are distinguished from MEMBRANE TRANSPORT PROTEINS, which move molecules across membranes, by the mode in which the molecules are transported. Transport Proteins, Vesicular

Related Publications

Megan S Lord, and Bill Cheng, and Fengying Tang, and J Guy Lyons, and Jelena Rnjak-Kovacina, and John M Whitelock
September 2018, Medicinal research reviews,
Megan S Lord, and Bill Cheng, and Fengying Tang, and J Guy Lyons, and Jelena Rnjak-Kovacina, and John M Whitelock
November 1983, The American journal of physiology,
Megan S Lord, and Bill Cheng, and Fengying Tang, and J Guy Lyons, and Jelena Rnjak-Kovacina, and John M Whitelock
November 1981, Journal of biochemistry,
Megan S Lord, and Bill Cheng, and Fengying Tang, and J Guy Lyons, and Jelena Rnjak-Kovacina, and John M Whitelock
January 1991, Revista do Hospital das Clinicas,
Megan S Lord, and Bill Cheng, and Fengying Tang, and J Guy Lyons, and Jelena Rnjak-Kovacina, and John M Whitelock
August 1990, Thrombosis and haemostasis,
Megan S Lord, and Bill Cheng, and Fengying Tang, and J Guy Lyons, and Jelena Rnjak-Kovacina, and John M Whitelock
April 1950, The Journal of clinical investigation,
Megan S Lord, and Bill Cheng, and Fengying Tang, and J Guy Lyons, and Jelena Rnjak-Kovacina, and John M Whitelock
January 1982, Revista paulista de medicina,
Megan S Lord, and Bill Cheng, and Fengying Tang, and J Guy Lyons, and Jelena Rnjak-Kovacina, and John M Whitelock
October 1947, The American journal of medicine,
Megan S Lord, and Bill Cheng, and Fengying Tang, and J Guy Lyons, and Jelena Rnjak-Kovacina, and John M Whitelock
May 2020, Journal de medecine vasculaire,
Megan S Lord, and Bill Cheng, and Fengying Tang, and J Guy Lyons, and Jelena Rnjak-Kovacina, and John M Whitelock
June 1975, Journal of clinical pathology,
Copied contents to your clipboard!